{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T16:51:57Z","timestamp":1774975917990,"version":"3.50.1"},"reference-count":45,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Information on the burden of postacute sequelae of SARS-CoV-2 infection (or long COVID) in patients with cancer during endemicity is limited.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the risk of postacute diagnoses and\/or symptoms compatible with long COVID in a population-based cohort of patients with cancer and high rates of vaccination and\/or boosting who were infected during Omicron predominance compared with those with negative test results (hereinafter, noninfected patients). Results were additionally stratified by COVID-19 severity and receipt of therapeutics.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective, population-based cohort study used health care claims databases to construct cohorts of adult patients with cancer in Singapore who were infected with SARS-CoV-2 during Omicron predominance (January 1 through December 31, 2022), and contemporaneous noninfected patients. Patients were followed up to 300 days from the index date and data were analyzed from February 1, 2022, through October 27, 2023.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n SARS-CoV-2 infection.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Competing risks regression (death as a competing risk), with overlap weights applied, was used to estimate risks of new-incident diagnoses and\/or symptoms compatible with long COVID following SARS-CoV-2 infection in patients with cancer compared with noninfected patients. Risks of postacute sequelae following COVID-19 hospitalization in patients with cancer were further contrasted against influenza hospitalizations (January 1, 2017, to December 31, 2022).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 76\u202f807 patients with cancer were included in the analysis (48 279 [62.9%] female); 39\u202f256 had SARS-CoV-2 infection and 37\u202f551 were noninfected patients. The mean (SD) age was 63.9 (13.7) years. The mean (SD) follow-up time was 263.1 (36.2) days for patients infected with SARS-CoV-2 and 264.8 (32.5) days for noninfected patients. Most patients had solid-organ cancer (72\u202f497 of 76 807 [94.4%]) and were boosted (71 550 of 76 807 [93.2%]); only a minority with SARS-CoV-2 infection (3571 of 39 256 [9.1%]) required acute hospitalization. No significant difference in risk of postacute diagnoses compatible with long COVID was observed in patients with SARS-CoV-2 infection (hazard ratio [HR],\u20090.98; 95% CI,\u20090.92-1.04) compared with noninfected patients. While risk of postacute symptoms following COVID-19 was modestly increased (HR,\u20091.09; 95% CI,\u20091.01-1.19;\n P<\/jats:italic>\n \u2009=\u2009.048), statistical significance was not attained after adjustment for multiple comparisons. However, significantly increased risk of postacute sequelae was observed among patients hospitalized for COVID-19 compared with noninfected patients (HR for any diagnosis,\u20091.36 [95% CI,\u20091.18-1.56]; HR for any symptom,\u20091.48 [95% CI,\u20091.22-1.76];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001 for both); risks remained elevated even among hospitalized cases receiving COVID-19 therapeutics. Risks of postacute sequelae following COVID-19 hospitalization in patients with cancer did not significantly differ from those associated with seasonal influenza hospitalizations.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The findings of this cohort study suggest that among highly boosted patients with cancer, the overall risk of postacute sequelae following Omicron SARS-CoV-2 infection was not significantly elevated compared with noninfected patients; however, patients who were hospitalized for COVID-19 remained at increased risk of postacute sequelae despite administration of COVID-19 therapeutics. These findings further suggest that COVID-19 vaccination and boosting remain important in mitigating the risk of long COVID among immunocompromised patients during endemicity.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.4037","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:30:23Z","timestamp":1774971023000},"page":"e264037","source":"Crossref","is-referenced-by-count":0,"title":["Postacute Sequelae Following Omicron COVID-19 in Patients With Cancer"],"prefix":"10.1001","volume":"9","author":[{"given":"Liang En","family":"Wee","sequence":"first","affiliation":[{"name":"Communicable Diseases Agency, Singapore"},{"name":"Duke-NUS Graduate Medical School, National University of Singapore, Singapore"},{"name":"Department of Infectious Diseases, Singapore General Hospital, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Ismail Bin","family":"Abdul Malek","sequence":"additional","affiliation":[{"name":"Communicable Diseases Agency, Singapore"},{"name":"National Centre for Infectious Diseases, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong Yi","family":"Tan","sequence":"additional","affiliation":[{"name":"Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jue Tao","family":"Lim","sequence":"additional","affiliation":[{"name":"Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei Chong","family":"Tan","sequence":"additional","affiliation":[{"name":"Duke-NUS Graduate Medical School, National University of Singapore, Singapore"},{"name":"Division of Medical Oncology, National Cancer Centre Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinghao Nicholas","family":"Ngiam","sequence":"additional","affiliation":[{"name":"Communicable Diseases Agency, Singapore"},{"name":"Division of Infectious Diseases, National University Hospital, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matilda","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Haematology-Oncology, National University Cancer Institute, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise Kiat Yee","family":"Vong","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tan Tock Seng Hospital, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Calvin J.","family":"Chiew","sequence":"additional","affiliation":[{"name":"Communicable Diseases Agency, Singapore"},{"name":"National Centre for Infectious Diseases, Singapore"},{"name":"Ministry of Health, Government of Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell Jingxian","family":"Li","sequence":"additional","affiliation":[{"name":"Communicable Diseases Agency, Singapore"},{"name":"National Centre for Infectious Diseases, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iain Bee Huat","family":"Tan","sequence":"additional","affiliation":[{"name":"Duke-NUS Graduate Medical School, National University of Singapore, Singapore"},{"name":"Division of Medical Oncology, National Cancer Centre Singapore, Singapore"},{"name":"Genome Institute of Singapore, Singapore"},{"name":"Saw Swee Hock School of Public Health, National University of Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Chien","family":"Lye","sequence":"additional","affiliation":[{"name":"Communicable Diseases Agency, Singapore"},{"name":"National Centre for Infectious Diseases, Singapore"},{"name":"Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore"},{"name":"Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore"},{"name":"Yong Loo Lin School of Medicine, National University of Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelvin Bryan","family":"Tan","sequence":"additional","affiliation":[{"name":"Communicable Diseases Agency, Singapore"},{"name":"Duke-NUS Graduate Medical School, National University of Singapore, Singapore"},{"name":"National Centre for Infectious Diseases, Singapore"},{"name":"Ministry of Health, Government of Singapore, Singapore"},{"name":"Saw Swee Hock School of Public Health, National University of Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"issue":"5","key":"zoi260160r1","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41579-024-01125-y","article-title":"The consequences of SARS-CoV-2 within-host persistence.","volume":"23","author":"Sigal","year":"2025","journal-title":"Nat Rev Microbiol"},{"issue":"5","key":"zoi260160r2","doi-asserted-by":"publisher","first-page":"e294","DOI":"10.1016\/S1473-3099(24)00769-2","article-title":"Targeting the SARS-CoV-2 reservoir in long COVID.","volume":"25","author":"Proal","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"zoi260160r3","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s43856-024-00549-0","article-title":"Identification of risk factors of long COVID and predictive modeling in the RECOVER EHR cohorts.","volume":"4","author":"Zang","year":"2024","journal-title":"Commun Med (Lond)"},{"key":"zoi260160r4","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.annepidem.2025.02.004","article-title":"Higher prevalence of long COVID observed in cancer survivors: insights from a US nationwide survey.","volume":"103","author":"Wang","year":"2025","journal-title":"Ann Epidemiol"},{"issue":"3","key":"zoi260160r5","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1136\/bmjebm-2023-112338","article-title":"How methodological pitfalls have created widespread misunderstanding about long COVID.","volume":"29","author":"H\u00f8eg","year":"2024","journal-title":"BMJ Evid Based Med"},{"key":"zoi260160r6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1506366","article-title":"Prevalence and risk factors for long COVID among cancer patients: a systematic review and meta-analysis.","volume":"14","author":"Xu","year":"2025","journal-title":"Front Oncol"},{"issue":"12","key":"zoi260160r7","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1016\/S1470-2045(21)00573-8","article-title":"Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study.","volume":"22","author":"Pinato","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"zoi260160r8","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.3390\/cancers15051497","article-title":"COVID-19 severity and survival over time in patients with hematologic malignancies: a population-based registry study.","volume":"15","author":"Mart\u00ednez-L\u00f3pez","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"7","key":"zoi260160r9","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/COC.0000000000001005","article-title":"Long COVID in cancer: a matched cohort study of 1-year mortality and long COVID prevalence among patients with cancer who survived an initial severe SARS-CoV-2 infection.","volume":"46","author":"Fankuchen","year":"2023","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"zoi260160r10","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.cmi.2024.12.002","article-title":"Booster vaccination and post\u2013COVID-19 condition during the Omicron variant-dominant wave: a large population-based study.","volume":"31","author":"Iba","year":"2025","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"zoi260160r11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S1470-2045(23)00056-6","article-title":"SARS-CoV-2 Omicron (B.1.1.529)\u2013related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry.","volume":"24","author":"Cortellini","year":"2023","journal-title":"Lancet Oncol"},{"issue":"23","key":"zoi260160r12","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70134","article-title":"Post-acute sequelae of COVID-19 in cancer patients: two cohorts in UK and Hong Kong.","volume":"13","author":"Wan","year":"2024","journal-title":"Cancer Med"},{"key":"zoi260160r13","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2023.100919","article-title":"Factors associated with delayed diagnosis of symptomatic adult COVID-19 cases presenting to primary care: a population-wide study during transition from Delta to Omicron BA.1 in Singapore.","volume":"41","author":"Tan","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"zoi260160r14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.puhe.2024.05.003","article-title":"Access to COVID-19 vaccination by socio-economic status in older Singaporean adults: a population-based cohort study.","volume":"233","author":"Wee","year":"2024","journal-title":"Public Health"},{"issue":"8","key":"zoi260160r15","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1093\/cid\/ciad345","article-title":"Long-term real-world protection afforded by third mRNA doses against symptomatic severe acute respiratory syndrome coronavirus 2 infections, coronavirus disease 19-related emergency attendances and hospitalizations amongst older Singaporeans during an Omicron XBB wave.","volume":"77","author":"Wee","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"10","key":"zoi260160r16","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.cmi.2024.06.011","article-title":"Long-term cardiovascular, cerebrovascular, and thrombotic complications after SARS-CoV-2-Omicron infection: a retrospective cohort study.","volume":"30","author":"Wee","year":"2024","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"zoi260160r17","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.cmi.2023.12.019","article-title":"Long-term neuropsychiatric sequelae of Delta versus Omicron SARS-CoV-2 infection.","volume":"30","author":"Wee","year":"2024","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"zoi260160r18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.30983","article-title":"Autoimmune sequelae after Delta or Omicron variant SARS-CoV-2 infection in a highly vaccinated cohort.","volume":"7","author":"Wee","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi260160r19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.cmi.2024.08.019","article-title":"Nirmatrelvir\/ritonavir treatment and risk for postacute sequelae of COVID-19 in older Singaporeans.","volume":"31","author":"Wee","year":"2025","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"zoi260160r20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004194","article-title":"Prevalence and characteristics of long COVID in elderly patients: an observational cohort study of over 2 million adults in the US.","volume":"20","author":"Fung","year":"2023","journal-title":"PLoS Med"},{"issue":"9","key":"zoi260160r21","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2023.2271","article-title":"COVID-19 severity and waning immunity after up to 4 mRNA vaccine doses in 73?608 patients with cancer and 621?475 matched controls in Singapore: a nationwide cohort study.","volume":"9","author":"Tan","year":"2023","journal-title":"JAMA Oncol"},{"issue":"1","key":"zoi260160r22","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/aje\/kwy201","article-title":"Addressing extreme propensity scores via the overlap weights.","volume":"188","author":"Li","year":"2019","journal-title":"Am J Epidemiol"},{"issue":"10","key":"zoi260160r23","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/j.cmi.2025.06.016","article-title":"Remdesivir and risk of long-term multi-systemic sequelae following COVID-19 hospitalization.","volume":"31","author":"Wee","year":"2025","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"zoi260160r25","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1093\/cid\/ciac320","article-title":"Enhanced infection prevention measures including universal N95 usage and daily testing: the impact on SARS-CoV-2 transmission in cohorted hospital cubicles through successive Delta and Omicron waves.","volume":"75","author":"Wee","year":"2022","journal-title":"Clin Infect Dis"},{"key":"zoi260160r26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.canep.2016.06.006","article-title":"Data quality at the Singapore Cancer Registry: an overview of comparability, completeness, validity and timeliness.","volume":"43","author":"Fung","year":"2016","journal-title":"Cancer Epidemiol"},{"issue":"8","key":"zoi260160r27","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1001\/jamainternmed.2023.2228","article-title":"Comparison of medical and mental health sequelae following hospitalization for COVID-19, influenza, and sepsis.","volume":"183","author":"Quinn","year":"2023","journal-title":"JAMA Intern Med"},{"issue":"3","key":"zoi260160r28","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1473-3099(23)00684-9","article-title":"Long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: a cohort study.","volume":"24","author":"Xie","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"zoi260160r29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2025.107946","article-title":"Long-term multisystemic sequelae post-hospitalisation for Omicron COVID-19 vs influenza: a retrospective cohort study.","volume":"158","author":"Wee","year":"2025","journal-title":"Int J Infect Dis"},{"issue":"9","key":"zoi260160r30","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/j.cmi.2025.04.022","article-title":"Long-term sequelae post-hospitalization for respiratory syncytial virus versus Omicron SARS-CoV-2 or influenza in adults and children: a retrospective cohort study.","volume":"31","author":"Wee","year":"2025","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"zoi260160r31","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.3201\/eid2608.201229","article-title":"Decreased influenza incidence under COVID-19 control measures, Singapore.","volume":"26","author":"Soo","year":"2020","journal-title":"Emerg Infect Dis"},{"issue":"11","key":"zoi260160r32","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.40985","article-title":"Long-lasting symptoms after an acute COVID-19 infection and factors associated with their resolution.","volume":"5","author":"Robineau","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"10","key":"zoi260160r33","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/s41577-023-00904-7","article-title":"The immunology of long COVID.","volume":"23","author":"Altmann","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"zoi260160r34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajt.2025.11.025","article-title":"Post-acute sequelae following Omicron COVID-19 in transplant recipients: a population-based cohort study.","author":"Wee","year":"2025","journal-title":"Am J Transplant"},{"issue":"4","key":"zoi260160r35","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/bjh.18700","article-title":"Mortality and burden of post\u2013COVID-19 syndrome have reduced with time across SARS-CoV-2 variants in haematology patients.","volume":"201","author":"Willan","year":"2023","journal-title":"Br J Haematol"},{"issue":"3","key":"zoi260160r36","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.1016\/S2666-5247(23)00336-1","article-title":"SARS-CoV-2 shedding and evolution in patients who were immunocompromised during the Omicron period: a multicentre, prospective analysis.","volume":"5","author":"Raglow","year":"2024","journal-title":"Lancet Microbe"},{"issue":"3","key":"zoi260160r37","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02050-23","article-title":"Humoral and cellular immune responses against SARS-CoV-2 post-vaccination in immunocompetent and immunocompromised cancer populations.","volume":"12","author":"Titova","year":"2024","journal-title":"Microbiol Spectr"},{"key":"zoi260160r38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104700","article-title":"Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXID.","volume":"94","author":"Chen","year":"2023","journal-title":"EBioMedicine"},{"issue":"12","key":"zoi260160r39","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.47618","article-title":"Cardiovascular events 1 year after respiratory syncytial virus infection in adults.","volume":"8","author":"Hviid","year":"2025","journal-title":"JAMA Netw Open"},{"key":"zoi260160r40","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2023.107680","article-title":"Vaccine hesitancy in cancer patients: a rapid review.","volume":"111","author":"Butow","year":"2023","journal-title":"Patient Educ Couns"},{"issue":"10","key":"zoi260160r41","doi-asserted-by":"publisher","first-page":"223","DOI":"10.46234\/ccdcw2023.041","article-title":"Hesitancy to receive the booster doses of COVID-19 vaccine among cancer patients in China: a multicenter cross-sectional survey\u2014four PLADs, China, 2022.","volume":"5","author":"Wang","year":"2023","journal-title":"China CDC Wkly"},{"issue":"2","key":"zoi260160r42","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3390\/vaccines11020239","article-title":"Factors influencing COVID-19 vaccine hesitancy among patients with serious chronic illnesses during the initial Australian vaccine rollout: a multi-centre qualitative analysis using the health belief model.","volume":"11","author":"Choi","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"zoi260160r43","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127091","article-title":"Behaviors, perceptions, and impact of the COVID-19 pandemic and vaccination on oncology patients in New Mexico with substantial representation of racial minorities and rural residents.","volume":"53","author":"Sasankan","year":"2025","journal-title":"Vaccine"},{"issue":"1","key":"zoi260160r44","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1080\/13696998.2025.2482372","article-title":"Characterizing the clinical and economic burden of COVID-19 among individuals with immunocompromising conditions in Ontario, Canada\u2014a matched, population-based observational study.","volume":"28","author":"Qian","year":"2025","journal-title":"J Med Econ"},{"issue":"2","key":"zoi260160r45","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1016\/S2665-9913(24)00224-8","article-title":"Association of nirmatrelvir-ritonavir with post-acute sequelae and mortality among patients who are immunocompromised with COVID-19 in Hong Kong: a retrospective cohort study.","volume":"7","author":"Lin","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"zoi260160r24","unstructured":"Government of Singapore, Ministry of Health. Easing of community safe management measures and border measures. March 24, 2022. Accessed December 31, 2025. https:\/\/www.moh.gov.sg\/newsroom\/easing-of-community-smms-and-border-measures\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2847136\/wee_2026_oi_260160_1774363827.1782.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:30:25Z","timestamp":1774971025000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2847136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.4037","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]}}}